Open Beta
MetriLume

US marketsCLNN

SEC-sourced researchBeta

CLNN

Clene Inc.

Company comparison ↗

Data passport

CIK
0001822791
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Nov 13, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 342,000.0000 USD; December 2025: 200,000.0000 USD342K USD0 USD0December 2024December 2025
CLNN · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024342,000.0000Mar 17, 2026
December 2025200,000.0000Mar 17, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025200,000.0000-26,173,000.0000-18,546,000.000018,131,000.000035,723,000.0000Mar 17, 2026
December 2024342,000.0000-39,400,000.0000-21,326,000.000027,337,000.000036,194,000.0000Mar 17, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

22/100
Profitability0
Growth8
Balance sheet0
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$200KJan 1, 2025 – Dec 31, 2025Mar 17, 202610-K
Previous period revenueRevenues$342KJan 1, 2024 – Dec 31, 2024Mar 17, 202610-K
Net incomeNetIncomeLoss-$26.17MJan 1, 2025 – Dec 31, 2025Mar 17, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$18.55MJan 1, 2025 – Dec 31, 2025Mar 17, 202610-K
Total assetsAssets$18.13MDec 31, 2025Mar 17, 202610-K
Total liabilitiesLiabilities$35.72MDec 31, 2025Mar 17, 202610-K

New filings

Explore methodology ↗